Physician profile
Murray Glusman
NPI 1295707990
$2,348.36
in general payments reported to CMS, 2019-2025
18 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $118 · 2021: $577 · 2022: $375 · 2023: $552 · 2024: $48.44 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.78 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $267.77 | 2020-2021 | |
| Allergan, INC. | $235.97 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.49 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $230.01 | 2022 | |
| Alcon Vision LLC | $221.96 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $197.95 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $158.44 | 2021-2023 | Myday Contact Lens |
| Dompe US, INC. | $135.56 | 2023-2025 | Oxervate |
| Glaukos Corporation | $135.26 | 2020-2025 | Idosetr |
| Apellis Pharmaceuticals, INC. | $122.11 | 2023 | Syfovre |
| Sun Pharmaceutical Industries INC. | $84.24 | 2023-2025 | Cequa |
| Shire North American Group INC | $65.96 | 2019 | |
| Kala Pharmaceuticals, INC. | $62.91 | 2019 | |
| Abbvie INC. | $55.65 | 2023 | |
| Sight Sciences, INC. | $47.43 | 2023 | Tearcare System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $34.66 | 2025 | |
| Harrow Eye, LLC | $31.86 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $29.13 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Glusman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.